Department of Radiation Oncology, Henry Ford Health System, Detroit, Michigan, USA.
Int J Radiat Oncol Biol Phys. 2012 May 1;83(1):178-84. doi: 10.1016/j.ijrobp.2011.05.052. Epub 2011 Oct 17.
The optimal adjuvant radiation treatment for endometrial carcinoma (EC) remains controversial. Adjuvant vaginal cuff brachytherapy (VB) has emerged as an increasingly common treatment modality. However, the time trends for using VB, external beam radiation therapy (EBRT), or combined therapy (VB+EBRT) have not been well characterized. We therefore examined the utilization trends of VB, EBRT, and VB+EBRT for adjuvant RT in International Federation of Gynecologic Oncology (FIGO) stage I and II EC over time.
We evaluated treatment patterns for 48,122 patients with EC diagnosed between January 1995 and December 2005, using the National Cancer Institute's Surveillance, Epidemiology, and End Results (SEER) public use database. Chi-squared tests were used to assess differences by radiation type (VB, EBRT, and VB+EBRT) and various demographic and clinical variables.
Analyses were limited to 9,815 patients (20.4%) with EC who met the inclusion criteria. Among women who received adjuvant RT, the proportion receiving VB increased yearly (12.9% in 1995 compared to 32.8% in 2005 (p < 0.0001). The increasing use of VB was proportional to the decreasing use of EBRT (56.1% in 1995 to 45.8% in 2005; p < 0.0001) and VB+EBRT (31.0% in 1995 to 21.4% in 2005; p < 0.001).
This population-based report demonstrates an increasing trend in the use of VB in the adjuvant setting after hysterectomy for treatment of women with FIGO stage I-II EC. VB alone appears to be replacing pelvic EBRT and VB+EBRT therapy in the management of stage I-II EC.
子宫内膜癌(EC)的最佳辅助放疗仍存在争议。辅助阴道袖口近距离放疗(VB)已成为一种越来越常见的治疗方式。然而,VB、外照射放疗(EBRT)或联合治疗(VB+EBRT)的使用趋势尚未得到很好的描述。因此,我们研究了 VB、EBRT 和 VB+EBRT 在国际妇产科联合会(FIGO)I 期和 II 期 EC 患者中的辅助放疗应用趋势随时间的变化。
我们使用国家癌症研究所的监测、流行病学和最终结果(SEER)公共使用数据库,评估了 1995 年 1 月至 2005 年 12 月期间 48122 例 EC 患者的治疗模式。使用卡方检验评估 VB、EBRT 和 VB+EBRT 之间的差异,以及各种人口统计学和临床变量。
分析仅限于符合纳入标准的 9815 例 EC 患者(20.4%)。在接受辅助放疗的女性中,VB 的使用比例逐年增加(1995 年为 12.9%,2005 年为 32.8%(p<0.0001)。VB 的使用增加与 EBRT 的使用减少成正比(1995 年为 56.1%,2005 年为 45.8%;p<0.0001)和 VB+EBRT(1995 年为 31.0%,2005 年为 21.4%;p<0.001)。
这项基于人群的报告表明,在子宫切除术后辅助治疗 FIGO I-II 期 EC 患者中,VB 的使用呈上升趋势。VB 似乎单独取代了盆腔 EBRT 和 VB+EBRT 治疗 I-II 期 EC。